N,N-dibenzylcyclopentanamine | 1421364-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-dibenzylcyclopentanamine
• CAS: 1421364-73-9
• 化学式: C₁₉H₂₃N
• 分子量: 265.398
• InChiKey: WRNWAZQLWRZXMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  碘代环戊烷 、 N,N-dibenzyl-O-benzoylhydroxylamine 在 三甲基氯硅烷 、 nickel dibromide 、 锌 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以77 %的产率得到N,N-dibenzylcyclopentanamine
  参考文献：
  名称：

  镍催化烷基亲电子试剂的胺化

  摘要：

  双分子亲核取代S N 2 是烷基亲电试剂胺化最早也是最重要的手段；其实际应用很大程度上限于初级或活化基质。此外，持续的挑战在于使用钯和镍催化剂在交叉偶联化学中从烷基底物建立C(sp 3 )–N键。因此，从烷基亲电子试剂构建C(sp 3 )–N键的方法仍然很少。现有的路线仅限于铜催化和光氧化还原催化。在这里，我们展示了一种替代的胺化策略，用于从可接近的烷基亲电子试剂中快速构建 C(sp 3 )–N 键，该策略在镍催化下通过 Ni (III) 物种高效还原消除用作自由基前体。

  DOI：

  10.1021/acs.orglett.3c02082

文献信息

• [EN] N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS<br/>[FR] DÉRIVÉS DE N-CYCLOHEXYLE-5-(THIAZOL-5-YL)-1 H-INDOLE-7-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE CD38 POUR AUGMENTER LA NAD+ ET POUR LE TRAITEMENT DE TROUBLES MUSCULAIRES, PAR EXEMPLE
  申请人：MITOBRIDGE INC

  公开号：WO2021087087A1

  公开（公告）日：2021-05-06

  The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).

  本发明涉及化合物I的一种或其药用可接受的盐。化合物I是CD38抑制剂，可用于治疗受益于NAD+增加的受试者的疾病或病况，或用于治疗受试者的线粒体疾病。这种疾病或病况可以是肌肉结构紊乱、神经激活紊乱、肌肉疲劳紊乱、肌肉质量紊乱、代谢性疾病、癌症、血管疾病、眼血管疾病、肌肉眼疾病或肾脏疾病。本描述披露了示例化合物的合成和表征，以及药理学数据（例如，第30至135页；示例1至61；表）。这样一个示例化合物是N-((1r,4r)-4-(2-甲氧基乙氧基)环己基)-5-(噻唑-5-基)-1H-吲哚-7-甲酰胺（II）。
• The synthesis of sterically hindered amines by a direct reductive amination of ketones
  作者：Niyaz Z. Yagafarov、Pavel N. Kolesnikov、Dmitry L. Usanov、Valentin V. Novikov、Yulia V. Nelyubina、Denis Chusov

  DOI：10.1039/c5cc08577b

  日期：——

  An atom-economical methodology for the synthesis of sterically hindered tertiary amines was developed, which is based on complementary Rh- and Ru-catalyzed direct reductive amination of ketones with primary and secondary...

  开发了一种原子经济的方法，用于合成位阻叔胺，该方法基于互补的Rh和Ru催化的酮与伯和仲的直接还原胺化反应。
• Coupling of Two Multistep Catalytic Cycles for the One-Pot Synthesis of Propargylamines from Alcohols and Primary Amines on a Nanoparticulated Gold Catalyst
  作者：Avelino Corma、Javier Navas、María J. Sabater

  DOI：10.1002/chem.201201837

  日期：2012.10.29

  A one‐pot reaction was performed with a nanoparticulated gold catalyst. A secondary amine is formed through N‐monoalkylation of a primary amine with an alcohol by a borrowing hydrogen methodology in a three‐step reaction. The secondary amine formed enters into a second A3‐coupling cycle to give propargylamines. The multistep reaction requires a gold species formed and stabilized on a ceria surface

  用纳米颗粒金催化剂进行单锅反应。仲胺是通过借用氢的方法在三步反应中将伯胺与醇进行N-单烷基化反应而形成的。形成的仲胺进入第二个A 3偶联循环，生成炔丙基胺。该多步反应需要在二氧化铈表面上形成并稳定的金物质。
• Pyrazolone Derivative
  申请人：Gomi Noriaki

  公开号：US20100324091A1

  公开（公告）日：2010-12-23

  A pyrazolone derivative represented by formula (I) below: wherein R 1 to R 3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

  本发明提供了一种由以下式（I）表示的吡唑酮衍生物：其中，R1至R3与权利要求中定义的相同；或其光学异构体、药学上可接受的盐或其水合物或溶剂化物。根据本发明，这种新型的吡唑酮衍生物具有PAI-1生产抑制活性、组织纤维化抑制活性和纤溶活性，对于预防和/或治疗组织纤维化疾病（肺纤维化、肾脏纤维化等）以及由病理性血栓引起的疾病（缺血性心脏病（心肌梗死和心绞痛）、心房血栓、肺栓塞、深静脉血栓性炎症、弥漫性血管内凝血、缺血性脑疾病（脑梗死、脑出血）和动脉硬化）非常有效。此外，本发明还提供了一种用于预防和/或治疗由纤溶酶原激活剂抑制物-1介导的疾病状况或症状的药物制剂，其包括根据本发明的新型吡唑酮衍生物。
• PYRAZOLONE DERIVATIVE
  申请人：Kowa Company, Ltd.

  公开号：EP2172458A1

  公开（公告）日：2010-04-07

  A pyrazolone derivative represented by formula (I) below: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

  下式（I）所代表的吡唑酮衍生物： 其中 R1 至 R3 与权利要求中定义的相同；或其光学异构体、药学上可接受的盐或其水合物或溶液。根据本发明的新型吡唑酮衍生物具有 PAI-1 生成抑制活性、组织纤维化抑制活性和纤维分解活性，可有效预防和/或治疗组织纤维化疾病（肺纤维化、肾纤维化等）和病理血栓形成疾病。例如缺血性心脏病（心肌梗塞和心绞痛）、心房血栓、肺栓塞、深部血栓性静脉炎、弥散性血管内凝血、缺血性脑部疾病（脑梗塞、脑出血）和动脉硬化。此外，还提供了一种用于预防和/或治疗由纤溶酶原激活剂抑制剂-1介导的疾病症状的药剂，其中包含根据本发明的新型吡唑酮衍生物。